Brind.

The FDA approved AYVAKIT from Blueprint Medicines for the treatment of advanced Systemic Mastocytosis and ISM, targeting the KIT D816V mutation.

1 report, 0 independent Updated Jun 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Blueprint Medicines (United States)FDA

Keep exploring

The entities involved

Blueprint Medicines (United States)
company in Cambridge, United States

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Jun 25Unknown outlet